Research highlights from the 2017 ERS International Congress: airway diseases in focus.

[en] For another year, high-quality research studies from around the world transformed the annual ERS International Congress into a vivid platform to discuss trending research topics, to produce new research questions and to further push the boundaries of respiratory medicine and science. This article reviews only some of the high-quality research studies on asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and chronic cough that were presented during the congress through the Airway Diseases Assembly (ERS Assembly 5) and places them into the context of current knowledge and research challenges.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Andersson, Cecilia

Bonvini, Sara J.

Horvath, Peter

Marquez, Eduardo

Satia, Imran

Kirkham, Paul

SCHLEICH, FLorence ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

Idzko, Marco

Gosens, Reinoud

Lopez-Campos, Jose Luis

More authors (5 more)

Language :

English

Title :

Research highlights from the 2017 ERS International Congress: airway diseases in focus.

Publication date :

January 2018

Journal title :

ERJ Open Research

eISSN :

2312-0541

Publisher :

European Respiratory Society, Sheffield, United Kingdom

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 May 2020

Statistics

Number of views

69 (2 by ULiège)

Number of downloads

34 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Pavord ID, Bush A, Holgate S. Asthma diagnosis: addressing the challenges. Lancet Respir Med 2015; 3: 339-341.
Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804-813.
Accordini S, Corsico AG, Braggion M, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013; 160: 93-101.
Koczulla AR, Vogelmeier CF, Garn H, et al. New concepts in asthma: clinical phenotypes and pathophysiological mechanisms. Drug Discov Today 2017; 22: 388-396.
Chung KF, Adcock IM. How variability in clinical phenotypes should guide research into disease mechanisms in asthma. Ann Am Thorac Soc 2013; 10: Suppl., S109-S117.
Bigler J, Boedigheimer M, Schofield JPR, et al. A severe asthma disease signature from gene expression profiling of peripheral blood from U-BIOPRED cohorts. Am J Respir Crit Care Med 2017; 195: 1311-1320.
Affleck K, Taylor A, Riley JH, et al. Late breaking abstract -comparison of the blood transcriptomic profiles of adults and children from the U-BIOPRED asthma study. Eur Respir J 2017; 50: Suppl. 61, OA3442.
Amelink M, de Nijs SB, de Groot JC, et al. Three phenotypes of adult-onset asthma. Allergy 2013; 68: 674-680.
Hekking P-P, Loza MJ, Pavlidis S, et al. Pathway discovery using transcriptomic profiles in adult-onset severe asthma. J Allergy Clin Immunol 2017; in press [https://doi.org/10.1016/j.jaci.2017.06.037].
Grainge CL, Davies DE. Epithelial injury and repair in airways diseases. Chest 2013; 144: 1906-1912.
Pavlidis S, Guo Y, Sun K, et al. Molecular evidence of Group 1 innate lymphoid cell activation in the U-BIOPRED cohort. Eur Respir J 2017; 50: Suppl. 61, OA278.
Farne HA, Johnston SL. Immune mechanisms of respiratory viral infections in asthma. Curr Opin Immunol 2017; 48: 31-37.
Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-1229.
Bizzintino J, Lee WM, Laing IA, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J 2011; 37: 1037-1042.
Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996; 154: 654-660.
Jackson DJ, Lemanske RF Jr. The role of respiratory virus infections in childhood asthma inception. Immunol Allergy Clin North Am 2010; 30: 513-522.
Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171: 137-141.
Edwards MR, Strong K, Cameron A, et al. Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol 2017; 140: 909-920.
Holt PG, Sly PD. Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest 2011; 139: 1165-1171.
Rubner FJ, Jackson DJ, Evans MD, et al. Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence. J Allergy Clin Immunol 2017; 139: 501-507.
Toussaint M, Jackson DJ, Swieboda D, et al. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nature Med 2017; 23: 681-691.
Danov O, Laßwitz L, Obernolte H, et al. Ex vivo virus infection of HDM-sensitized lung tissue proves inadequate anti-viral immune response in small airways. Eur Respir J 2017; 50: Suppl. 61, PA1140.
Lin J, Zhao GQ, Wang Q, et al. Regulation of interleukin 33/ST2 signaling of human corneal epithelium in allergic diseases. Int J Ophthalmol 2013; 6: 23-29Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genome-wide association study of asthma. N Engl J Med 2010; 363: 1211-1221.
Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genome-wide association study of asthma. N Engl J Med 2010; 363: 1211-1221.
Ravanetti L, Dijkhuis A, Sabogal Pineros Y, et al. Late breaking abstract -IL-33 drives influenza-induced exacerbations of asthma by halting anti-viral and Th1 responses. Eur Respir J 2017; 50: Suppl. 61, PA1138.
Haccuria A, Virreira M, Rascchaert J, et al. IL-33 mRNA in induced sputum cells from allergic rhinitis and asthma patients: a marker of Th-2 phenotype status? Eur Respir J 2017; 50: Suppl. 61, PA4767.
Perkins T, Oczypok E, Dutz R, et al. RAGE-dependent VCAM-1 expression in the pulmonary endothelium mediates IL-33 induced asthma pathogenesis. Eur Respir J 2017; 50: Suppl. 61, PA4917.
Prefontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183: 5094-5103.
Kamekura R, Kojima T, Takano K, et al. The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy 2012; 42: 218-228.
Mizutani N, Nabe T, Yoshino S. Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology 2013; 139: 205-218.
Lynch JP, Werder RB, Simpson J, et al. Aeroallergen-induced IL-33 predisposes to respiratory virus-induced asthma by dampening antiviral immunity. J Allergy Clin Immunol 2016; 138: 1326-1337.
Werder RB, Zhang V, Lynch JP, et al. Chronic IL-33 expression predisposes to viral-induced exacerbations of asthma by increasing type 2 inflammation and dampening antiviral immunity. J Allergy Clin Immunol 2017; in press [https://doi.org/10.1016/j.jaci.2017.07.051].
Upham, J, Jurak L, Xi Y. IL-33 augments rhinovirus-induced type 2 immune responses in asthma via selective upregulation of one chain of the IL-33 receptor. Eur Respir J 2017; 50: Suppl. 61, PA567.
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017; 49: 1700214.
Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 196: 438-446.
Naya I, Barnacle H, Birk R, et al. Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study. Eur Respir J 2017; 50: Suppl. 61, PA3248.
Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389: 1919-1929.
Singh D, Papi A, Vezzoli S, et al. Effect of CHF5993 pMDI (extrafine beclometasone dipropionate: BDP, formoterol fumarate: FF, glycopyrronium bromide: GB) on clinically important deteriorations (CID) in COPD: post-hoc analysis of TRINITY study. Eur Respir J 2017; 50: Suppl. 61, PA3949.
Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016; 388: 963-973.
Singh D, Fabbri L, Pappi A, et al. Late breaking abstract -extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY. Eur Respir J 2017; 50: Suppl. 61, OA2898.
Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374: 2222-2234.
Bjermer L, Roche N, Gutzwiller FS, et al. Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: results from the FLAME study. Eur Respir J 2017; 50: Suppl. 61, PA936.
Anzueto, AR, Kostikas K, Shen S, et al. Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol/fluticasone (SFC): the FLAME study. Eur Respir J 2017; 50: Suppl. 61, PA3255.
Wedzicha J, Vogelmeier CF, Ayers T, et al. Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study. Eur Respir J 2017; 50: Suppl. 61, PA1075.
Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM2 and AUGMENT). Respir Res 2015; 16: 92.
Singh D, D'Urzo AD, Donohue JF, et al. Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy. Eur Respir J 2017; 50: Suppl. 61, PA679.
Watz H, Troosters T, Beeh KM, et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. Eur Respir J 2017; 50: Suppl. 61, PA687.
Worth H, Buhl R, Criée CP, et al. GOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational study. Respir Med 2017; 131: 77-84.
Buhl R, Criée C-P, Kardos P, et al. Low rate of exacerbations following initiation of LABA/LAMA fixed-dose combinations: an analysis of the DACCORD real life study. Eur Respir J 2017; 50: Suppl. 61, PA1070.
Gosset P, Kone B, Perez-Cruz M, et al. The TLR5 agonist flagellin prevents bacteria-induced chronic obstructive pulmonary disease exacerbations in mice. Eur Respir J 2017; 50: Suppl. 61, OA1490.
To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012; 12: 204.
Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health 2015; 5: 020415.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389: 1919-1929.
Bafadhel M, Davies L, Calverley PM, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014; 44: 789-791.
Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370: 2102-2110.
Chen R, Smith SG, Salter B, et al. Allergen-induced increases in sputum levels of Group 2 innate lymphoid cells in subjects with asthma. Am J Respir Crit Care Med 2017; 196: 700-712.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017; 377: 936-946.
Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913.
Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017; 377: 1613-1629.
Chalmers JD, Finch S, Shteinberg M, et al. Late breaking abstract -the prevalence and burden of Pseudomonas aeruginosa among bronchiectasis patients in Europe -data from the FRIENDS cohort. Eur Respir J 2017; 50: Suppl. 61, OA1967.
Smith A, Choi J-Y, Finch S, et al. Sputum pregnancy zone protein (PZP) -a potential biomarker of bronchiectasis severity. Eur Respir J 2017; 50: Suppl. 61, OA1969.
Froehlich J, Dahms J, Cipolla D, et al. Late breaking abstract -reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline. Eur Respir J 2017; 50: Suppl. 61, OA466.
Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-615.
Menzel M, Akbarshahi H, Bjermer L, et al. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep 2016; 6: 28698.
Wu Q, Shen W, Cheng H, et al. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014; 19: 321-329.
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259.
Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260-1267.
Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (bronchiectasis intervention study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 610-620.
Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
Mertsch P, Rademacher J, de Roux A, et al. PROGNOSIS -the German Bronchiectasis Registry: first results. Eur Respir J 2017; 50: (Suppl. 61) PA4059.
Dhar R, Chandrashekariah S, Dsouza G, et al. Phenotype characterization of non-cystic fibrosis bronchiectasis in India. Eur Respir J 2017; 50: Suppl. 61, PA4058.
Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Heath Statistics 2011; 12: 1-38.
Pratter MR. Cough and the common cold: ACCP evidence-based clinical guidelines. Chest 2006; 129: 72S-74S.
French CL, Irwin RS, Curley FJ, et al. Impact of chronic cough on quality of life. Arch Intern Med 2010; 158: 1657-1661.
Irwin RS, French CT, Lewis SZ, et al. Overview of the management of cough: CHEST guideline and expert panel report. Chest 2014; 146: 885-889.
Pacheco A. Chronic cough: from a complex dysfunction of the neurological circuit to the production of persistent cough. Thorax 2014; 69: 881-883.
Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2015; 385: 1198-1205.
Smith J, Kitt M, Morice A, et al. Inhibition of P2X3 by MK-7264 reduces 24-hour cough frequency in a randomized, controlled, Phase 2b clinical trial. Eur Respir J 2017; 50: Suppl. 61, OA2932.
Morice AH, Kitt M, Ford A, et al. The Effect of MK-7264, a P2X3 antagonist, on cough reflex sensitivity in a randomized crossover trial of healthy and chronic cough subjects. Eur Respir J 2017; 50: Suppl. 61, OA2931.
Bonvini S, Dubuis E, Adcock J, et al. Activation of transient receptor potential (TRP) channels by hypoosmolar solution: an endogenous mechanism of ATP release and afferent nerve activation. Eur Respir J 2017; 50: Suppl. 61, OA4410.
Dicpinigatis P, Canning B, DeVita R, et al. The antitussive effects of alpha7 (α7) nicotinic receptor agonists. Eur Respir J 2017; 50: Suppl. 61, OA4409.
Wortley M, Bonvini S, Maher S, et al. EP2 & EP4 receptor agonists inhibit the airway sensory nerves that cause cough, a potential protective control that is lost in human smokers and a pre-clinical COPD model. Eur Respir J 2017; 50: Suppl. 61, OA1491.